Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab + Bevacizumab in Spanish HCC patients
NCT04732286Phase 3Terminated
- Sponsor
- Roche
- Start
- May 2021
- Primary completion
- Apr 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of atezolizumab in hepatocellular carcinoma (HCC), sponsored by Roche. Started May 2021; status: terminated.
02
Drugs
atezolizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04732286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04732286.